Clinical Trial

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Recruiting
View on ClinicalTrials.gov →
Summary
This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2020-03-27; most recent amendment 2026-03-02.
Trial Details
NCT Number NCT04328298
Lead Sponsor The Lymphoma Academic Research Organisation
Collaborators: Gilead Sciences, Novartis, Bristol-Myers Squibb
Conditions Hematopathology Eligible or CAR-t Cell Treatment
Enrollment 5,000 participants
Start Date 2019-12-19
Primary Completion 2038-12-19 (estimated)
Study Completion 2038-12-19 (estimated)
Updated on ClinicalTrials.gov 2026-03-04